IP Library Granted Patent US 8,114,384
Granted Patent B2
US 8,114,384 · App. 10/890,704 · Granted Feb 14, 2012

Process for the production of an abuse-proofed solid dosage form

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,114,384
App. No.
10/890,704
Granted
Feb 14, 2012
Kind
B2
Abstract

The present invention relates to a process for the production of an abuse-proofed solid dosage form containing at least one active ingredient with potential for abuse and a synthetic or natural polymer with a breaking strength of =500 N, characterized in that a corresponding mixture is processed by melt extrusion with the assistance of a planetary-gear extruder.

Claims (14)

1. A process for the production of an abuse-proofed solid dosage form with a breaking strength of at least 500N, said dosage form comprising at least one opioid active ingredient with potential for abuse and 50-99.9 wt%, relative to the total weight of the dosage form, of polyethylene oxide having a molecular weight of at least one million Daltons, said process comprising heating a mixture comprising the at least one opioid active ingredient with potential for abuse and the polyethylene oxide in a planetary-gear extruder at least until the polyethylene oxide has softened, and thereafter compacting and extruding the mixture with the planetary-gear extruder into formed articles, which are optionally subjected to singulation and shaping to yield a nonmultiparticulate dosage form with a breaking strength of at least 500 N.

2. A process according to claim 1 , wherein the active ingredient is selected from the group consisting of oxycodone, morphine, hydromorphone, tramadol and the physiologically acceptable salts thereof.

3. A process according to claim 1 , wherein the mixture additionally comprises further auxiliary substances.

4. A process according to claim 1 , wherein the planerary-gear extruder has at least three planetary spindles.

5. A process according to claim 1 , wherein the planetary-gear extruder has a feed screw and a central spindle with planetary spindles.

6. A process according to claim 1 , wherein the formed articles are finally formed and optionally singulated.

7. A process according to claim 1 , wherein the formed articles are formed into tablets.

8. A process according to claim 7 , wherein the tablets are formed with press molding with the assistance of two counter-rotating rolls with mutually opposing recesses, the construction of which recesses determines the tablet shape.

9. A process according to claim 7 , wherein the tablets are in each case formed with the assistance of a die and at least one shaping punch.

10. An abuse-proofed dosage form with a breaking strength of at least 500N obtainable by a process according to claim 1 .

11. A process according to claim 2 , where the active ingredient is the hydrochloride of oxycodone, morphine, hydromorphine, or tramadol.

12. A process according to claim 3 , where the further auxiliary substances are one or more substances selected from the group consisting of waxes (D), antioxidants and plasticizers.

13. A process according to claim 1 , where the opioid is in a form selected from the group consisting of physiologically acceptable enantiomers, stereoisomers, diastereomers, racemates and derivatives thereof.

14. A process of claim 13 , where the physiologically acceptable derivatives thereof are selected from the group consisting of ethers, esters and amides.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2017
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: ENDO PHARMACEUTICALS, INC.; ENDO PHARMACEUTICALS SOLUTIONS, INC.; ASTORA WOMEN'S HEALTH HOLDINGS, LLC
Reel/Frame 042362/0001 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF RECEIVING PARTY IN RELEASE OF PATENT SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS PREVIOUSLY RECORDED ON REEL 032380 FRAME 0157. ASSIGNOR(S) HEREBY CONFIRMS THE RELEASE OF SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS.. Recorded Mar 24, 2014
From: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
To: ENDO PHARMACEUTICALS INC.
Reel/Frame 032513/0255 →
GRANT OF SECURITY INTEREST IN LICENSED PATENTS Recorded Mar 20, 2014
From: ENDO PHARMACEUTICALS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 032491/0620 →
RELEASE OF PATENT SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS Recorded Mar 3, 2014
From: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
To: ENDO PHARMACEUTICALS SOLUTIONS INC.
Reel/Frame 032380/0157 →
RELEASE OF SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS RECORDED AT REEL/FRAME 25456/172 Recorded Jul 12, 2011
From: JPMORGAN CHASE BANK N.A., AS ADMINISTRATIVE AGENT
To: ENDO PHARMACEUTICALS INC.
Reel/Frame 026577/0357 →
SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS Recorded Jul 8, 2011
From: ENDO PHARMACEUTICALS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
Reel/Frame 026561/0978 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS (EXCLUSIVELY LICENSED PATENTS) Recorded Dec 9, 2010
From: ENDO PHARMACEUTICALS INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 025456/0172 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2008
From: ARKENAU, ELISABETH, DR.; BARTHOLOMAUS, JOHANNES, DR.
To: GRUENENTHAL GMBH
Reel/Frame 021842/0654 →